Sage Therapeutics (SAGE) Competitors $8.80 +0.04 (+0.46%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$8.80 +0.00 (+0.06%) As of 07/25/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. AGIO, TWST, INDV, RXRX, DNLI, BEAM, KNSA, BLTE, CNTA, and VCELShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Its Competitors Agios Pharmaceuticals Twist Bioscience Indivior Recursion Pharmaceuticals Denali Therapeutics Beam Therapeutics Kiniksa Pharmaceuticals International Belite Bio Centessa Pharmaceuticals Vericel Sage Therapeutics (NASDAQ:SAGE) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Do analysts rate SAGE or AGIO? Sage Therapeutics currently has a consensus price target of $8.02, suggesting a potential downside of 8.92%. Agios Pharmaceuticals has a consensus price target of $57.33, suggesting a potential upside of 43.33%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 1 Sell rating(s) 14 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.93Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has stronger valuation and earnings, SAGE or AGIO? Agios Pharmaceuticals has lower revenue, but higher earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$41.24M13.36-$400.67M-$5.80-1.52Agios Pharmaceuticals$36.50M63.47$673.72M$11.243.56 Is SAGE or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,798.26% compared to Sage Therapeutics' net margin of -747.63%. Agios Pharmaceuticals' return on equity of -2.75% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-747.63% -68.99% -60.67% Agios Pharmaceuticals 1,798.26%-2.75%-2.52% Do insiders and institutionals hold more shares of SAGE or AGIO? 99.2% of Sage Therapeutics shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Comparatively, 4.3% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, SAGE or AGIO? Sage Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Does the media prefer SAGE or AGIO? In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Sage Therapeutics. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 4 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 1.00 beat Agios Pharmaceuticals' score of 0.57 indicating that Sage Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sage Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAgios Pharmaceuticals beats Sage Therapeutics on 12 of the 16 factors compared between the two stocks. Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$548.56M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-1.5221.1828.1020.05Price / Sales13.36286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book1.168.378.665.87Net Income-$400.67M-$55.19M$3.25B$258.55M7 Day Performance-3.40%5.88%4.22%3.73%1 Month Performance-5.17%17.33%10.51%11.75%1 Year Performance-19.93%4.42%34.40%18.03% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics3.4092 of 5 stars$8.80+0.5%$8.02-8.9%-16.0%$548.56M$41.24M-1.52690News CoverageUpcoming EarningsAGIOAgios Pharmaceuticals4.3602 of 5 stars$39.23+0.5%$58.60+49.4%-17.5%$2.27B$37.04M3.49390Upcoming EarningsAnalyst ForecastTWSTTwist Bioscience4.3776 of 5 stars$37.80-0.6%$50.40+33.3%-37.4%$2.26B$312.97M-11.63990News CoveragePositive NewsINDVIndivior1.1456 of 5 stars$15.62+1.0%$17.00+8.8%+30.9%$2.15B$1.17B-50.391,051News CoverageAnalyst ForecastRXRXRecursion Pharmaceuticals0.7942 of 5 stars$5.28flat$7.00+32.6%-19.4%$2.15B$59.82M-2.98400DNLIDenali Therapeutics4.2644 of 5 stars$14.69+1.2%$33.71+129.5%-43.3%$2.13B$330.53M-5.50430News CoveragePositive NewsUpcoming EarningsBEAMBeam Therapeutics2.2287 of 5 stars$21.17+0.0%$48.75+130.3%-32.5%$2.13B$63.52M-4.59510Analyst RevisionKNSAKiniksa Pharmaceuticals International3.4615 of 5 stars$28.80+2.5%$39.33+36.6%+1.6%$2.10B$423.24M-115.20220News CoverageBLTEBelite Bio1.7877 of 5 stars$63.58+0.6%$96.67+52.0%+28.7%$2.02BN/A-46.7510High Trading VolumeCNTACentessa Pharmaceuticals3.3291 of 5 stars$15.13+4.9%$27.89+84.3%+49.8%$2.02B$15M-8.36200Insider TradeHigh Trading VolumeVCELVericel3.6821 of 5 stars$39.82-0.3%$61.14+53.5%-22.4%$2.00B$238.54M1,327.78300News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Agios Pharmaceuticals Competitors Twist Bioscience Competitors Indivior Competitors Recursion Pharmaceuticals Competitors Denali Therapeutics Competitors Beam Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Belite Bio Competitors Centessa Pharmaceuticals Competitors Vericel Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAGE Stock Alerts